Our Company
Ikaria is a biotherapeutics company whose acute care therapies address the significant unmet needs of critically ill patients. Our deep understanding of the biology of critical conditions, unique insight into the clinical picture of critically ill patients, and our working knowledge of the needs of critical care providers fuel our efforts. We strive to provide the advanced therapies and clinical support caregivers need to intervene in the most urgent situations.
Csaba Szabo, MD, PhD
We are passionate about science
At Ikaria, advancing critical care science is crucial. Our Chief Scientific Officer, Csaba Szabo, MD, PhD, has devoted his professional life to the study of the pathogenetic mechanisms and experimental therapy of critical illness. He leads our team of scientists conducting early-stage research in Seattle, WA, continually testing new ideas that will hopefully address areas of significant unmet needs.
Dr. Szabo is a leading figure in the area of the cellular mechanisms
and experimental therapy of critical illness — he is a sought-after
guest lecturer at major critical care meetings, and serves on the editorial
boards of several prestigious journals. With over 500 full, peer-reviewed publications and 13,000 independent
citations, Dr. Szabo is the seventh most-frequently cited pharmacologist
in the world (Thomson-ISI, 2009).
Dr. Szabo also is an Adjunct Professor in the Department of Anesthesiology
at the University of Texas Medical Center in Galveston. Prior to joining
Ikaria in 2006, Dr. Szabo co-founded Inotek Pharmaceuticals, Inc.,
a company in which he progressed five drug-development candidate small
molecules from ideation to clinical trials. From
Dr. Szabo received his MD from Semmelweis University Medical School in Budapest, and a DSci from the Hungarian Academy of Sciences. He also holds two PhD degrees in physiology (Semmelweis University) and pharmacology (University of London), and conducted his postdoctoral training in pharmacology with Nobel Laureate Sir John Vane.
We revel in the possibilities
Mark Roth, PhD
Mark Roth, PhD, founding Ikaria scientist and cell biologist at the Fred Hutchinson Cancer Research Center, believes anything is possible, including suspended animation and reanimation—the ability to control metabolic activity. Work in this area could mean buying precious time for critical care patients. We are currently exploring the therapeutic possibilities of this exciting new concept.